Apotex's Ruxolitinib Modifications
Apotex developed a Paragraph IV ANDA challenging Incyte's patents on ruxolitinib (Jakafi), the JAK1/JAK2 inhibitor for myelofibrosis and polycythemia vera. Their formulation modifies the chemical structure by creating ruxolitinib citrate, a salt form of the active drug substance, instead of the patented ruxolitinib phosphate used in Jakafi.[1][2]
This salt switch alters the counterion (citrate vs. phosphate), potentially affecting solubility, stability, and bioavailability while preserving the core pyrazolopyrimidine scaffold:
<br />
Core ruxolitinib cation (unchanged):<br />
N<br />
/ \<br />
N C-(CH2)2-Ph-3-CN<br />
| |<br />
C=N CH-(CH2)3-N(Me)2<br />
\ /<br />
C-NH2<br />
- Phosphate salt (Incyte): Pairs with HPO4^2-, claimed for specific crystal forms in patents like US 7,598,257.
- Citrate salt (Apotex): Pairs with C6H8O7^-, enabling a non-infringing polymorphic form.[3]
Why This Counts as a Modification
Salt forms are distinct chemical entities under FDA rules, often used to bypass composition-of-matter patents. Apotex's citrate version avoids Incyte's phosphate-specific claims without changing therapeutic activity.[4]
Patent Litigation Timeline
- 2016: Apotex files ANDA; Incyte sues for infringement (Del. Dist. Ct., 1-16-cv-00989).
- 2021: Court rules Apotex's citrate salt does not infringe US 8,158,616 (phosphate polymorph), but upholds other patents.
- 2023: Settlement allows Apotex launch no earlier than June 2028, pending appeals.[5][6]
When Does Ruxolitinib Patent Expiry Hit?
Core patents expire 2027-2033; pediatric exclusivity adds six months. Apotex's entry hinges on settlement, not full expiry.[1]
Biosimilar or Generic Entry Risks
No true biosimilar (ruxolitinib is small-molecule). Competitors like Celgene/Sandoz pursue similar salt strategies, but litigation delays generics until ~2028.[7]
Sources
[1]: DrugPatentWatch.com - Ruxolitinib Patents
[2]: FDA Orange Book, Ruxolitinib approvals
[3]: US Patent 7,598,257 (Incyte phosphate claims)
[4]: 21 CFR 314.94 (ANDA salt provisions)
[5]: Incyte v. Apotex, 1-16-cv-00989 (D. Del. 2021 ruling)
[6]: Law360, "Incyte, Apotex Settle Ruxolitinib Hatch-Waxman Fight" (2023)
[7]: DrugPatentWatch.com - Ruxolitinib Paragraph IV Challenges